[
    {
        "file_name": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT.txt",
        "perturbation": [
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "MD Anderson represents and undertakes that (a) *** and (b) that the ***   (together (a) and (b) being the ***):   1.2  Adaptimmune shall be the sponsor of any Clinical Study. MDACC shall be responsible for the conduct of each Study in accordance with the relevant protocol and/or workscope.",
                "changed_text": "MD Anderson represents and undertakes that (a) *** and (b) that the ***   (together (a) and (b) being the ***):   1.2  Adaptimmune Limited shall be the sponsor of any Clinical Study. MDACC shall be responsible for the conduct of each Study in accordance with the relevant protocol and/or workscope.",
                "explanation": "The contract introduces 'Adaptimmune' in Section 1.1 but then uses the term 'Adaptimmune Limited' to refer to the same role, it creates ambiguity as to which entity has legal responsibility, and if the terms are interchangeable.",
                "location": "Section 1.1 and 1.2"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "In relation to Pre-Clinical Studies, oral reports or interim written status reports of the progress of the Studies will be provided by the Principal Investigator to Adaptimmune on a regular basis and at least once every *** (***) months during the course of a Study. Significant developments arising out of Studies will be communicated promptly to Adaptimmune.",
                "changed_text": "In relation to Pre-Clinical Studies, oral reports or interim written status reports of the progress of the Studies will be provided by the Lead Researcher to Adaptimmune on a regular basis and at least once every *** (***) months during the course of a Study. Significant developments arising out of Studies will be communicated promptly to Adaptimmune.",
                "explanation": "This change replaces \"Principal Investigator\" with \"Lead Researcher.\" Without a clear definition that these terms are interchangeable, it's uncertain who is responsible for providing the reports, potentially causing confusion regarding the reporting obligations.",
                "location": "Section 6.1"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "MD Anderson will provide to Adaptimmune a detailed written disclosure of each patentable invention and/or discovery (and all intellectual property rights therein) conceived and reduced to practice in the conduct of a Study and arising from the performance of a Study (\"Invention\") promptly after a written invention disclosure report for such Invention is received by MD Anderson's Office of Technology Commercialization.",
                "changed_text": "MD Anderson will provide to Adaptimmune a detailed written disclosure of each patentable product and/or discovery (and all intellectual property rights therein) conceived and reduced to practice in the conduct of a Study and arising from the performance of a Study (\"Invention\") promptly after a written invention disclosure report for such Invention is received by MD Anderson's Office of Technology Commercialization.",
                "explanation": "The term \"patentable invention\" is replaced with \"patentable product\". The term invention is a defined term, while product is not. It creates ambiguity as to the scope of disclosure obligations, because product could mean a tangible result, and whether it is a component of the invention.",
                "location": "Section 7.3"
            }
        ]
    }
]